EP Patent

EP2934494B1 — Pharmaceutical formulation of n- [5- [2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Assigned to AstraZeneca AB · Expires 2019-06-12 · 7y expired

What this patent protects

Patent listed against Amoxil.

Drugs covered by this patent

Patent Metadata

Patent number
EP2934494B1
Jurisdiction
EP
Classification
—
Expires
2019-06-12
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.